questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Globulines
Sérum-globulines
Immunoglobulines
Anticorps
Anticorps : Questions médicales fréquentes
Termes MeSH sélectionnés :
Relative Biological Effectiveness
Diagnostic
5
Anticorps
Tests sérologiques
Anticorps
Immunofluorescence
Symptômes
5
Réponse immunitaire
Symptômes
Anticorps
Maladies infectieuses
Anticorps
Maladies auto-immunes
Anticorps
Infections virales
Prévention
5
Système immunitaire
Prévention
COVID-19
Anticorps monoclonaux
Traitements
5
Anticorps monoclonaux
Thérapie
Anticorps
Prévention des maladies
Anticorps
Effets secondaires
Complications
5
Anticorps
Maladies auto-immunes
Anticorps
Réactions allergiques
Anticorps monoclonaux
Complications
Anticorps
Interactions médicamenteuses
Maladies auto-immunes
Complications
Facteurs de risque
5
Facteurs de risque
Maladies auto-immunes
Habitudes alimentaires
Anticorps
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Anticorps : Questions médicales les plus fréquentes",
"headline": "Anticorps : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Anticorps : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-30",
"dateModified": "2025-04-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Anticorps"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Immunoglobulines",
"url": "https://questionsmedicales.fr/mesh/D007136",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobulines",
"code": {
"@type": "MedicalCode",
"code": "D007136",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-idiotypiques",
"alternateName": "Antibodies, Anti-Idiotypic",
"url": "https://questionsmedicales.fr/mesh/D000888",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-idiotypiques",
"code": {
"@type": "MedicalCode",
"code": "D000888",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.071"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-archéens",
"alternateName": "Antibodies, Archaeal",
"url": "https://questionsmedicales.fr/mesh/D019844",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-archéens",
"code": {
"@type": "MedicalCode",
"code": "D019844",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.107"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antibactériens",
"alternateName": "Antibodies, Bacterial",
"url": "https://questionsmedicales.fr/mesh/D000907",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antibactériens",
"code": {
"@type": "MedicalCode",
"code": "D000907",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.125"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Antistreptolysine",
"alternateName": "Antistreptolysin",
"url": "https://questionsmedicales.fr/mesh/D000989",
"about": {
"@type": "MedicalCondition",
"name": "Antistreptolysine",
"code": {
"@type": "MedicalCode",
"code": "D000989",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.125.288"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Anticorps bispécifiques",
"alternateName": "Antibodies, Bispecific",
"url": "https://questionsmedicales.fr/mesh/D018033",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps bispécifiques",
"code": {
"@type": "MedicalCode",
"code": "D018033",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.134"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps bloquants",
"alternateName": "Antibodies, Blocking",
"url": "https://questionsmedicales.fr/mesh/D019138",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps bloquants",
"code": {
"@type": "MedicalCode",
"code": "D019138",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.143"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps catalytiques",
"alternateName": "Antibodies, Catalytic",
"url": "https://questionsmedicales.fr/mesh/D017151",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps catalytiques",
"code": {
"@type": "MedicalCode",
"code": "D017151",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.167"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antifongiques",
"alternateName": "Antibodies, Fungal",
"url": "https://questionsmedicales.fr/mesh/D000908",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antifongiques",
"code": {
"@type": "MedicalCode",
"code": "D000908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.179"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antihelminthe",
"alternateName": "Antibodies, Helminth",
"url": "https://questionsmedicales.fr/mesh/D000909",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antihelminthe",
"code": {
"@type": "MedicalCode",
"code": "D000909",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.185"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps hétérophiles",
"alternateName": "Antibodies, Heterophile",
"url": "https://questionsmedicales.fr/mesh/D000910",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps hétérophiles",
"code": {
"@type": "MedicalCode",
"code": "D000910",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.191"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps monoclonaux",
"alternateName": "Antibodies, Monoclonal",
"url": "https://questionsmedicales.fr/mesh/D000911",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps monoclonaux",
"code": {
"@type": "MedicalCode",
"code": "D000911",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps monoclonaux humanisés",
"alternateName": "Antibodies, Monoclonal, Humanized",
"url": "https://questionsmedicales.fr/mesh/D061067",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps monoclonaux humanisés",
"code": {
"@type": "MedicalCode",
"code": "D061067",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adalimumab",
"alternateName": "Adalimumab",
"url": "https://questionsmedicales.fr/mesh/D000068879",
"about": {
"@type": "MedicalCondition",
"name": "Adalimumab",
"code": {
"@type": "MedicalCode",
"code": "D000068879",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alemtuzumab",
"alternateName": "Alemtuzumab",
"url": "https://questionsmedicales.fr/mesh/D000074323",
"about": {
"@type": "MedicalCondition",
"name": "Alemtuzumab",
"code": {
"@type": "MedicalCode",
"code": "D000074323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Basiliximab",
"alternateName": "Basiliximab",
"url": "https://questionsmedicales.fr/mesh/D000077552",
"about": {
"@type": "MedicalCondition",
"name": "Basiliximab",
"code": {
"@type": "MedicalCode",
"code": "D000077552",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.407"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Bévacizumab",
"alternateName": "Bevacizumab",
"url": "https://questionsmedicales.fr/mesh/D000068258",
"about": {
"@type": "MedicalCondition",
"name": "Bévacizumab",
"code": {
"@type": "MedicalCode",
"code": "D000068258",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.438"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Brentuximab védotine",
"alternateName": "Brentuximab Vedotin",
"url": "https://questionsmedicales.fr/mesh/D000079963",
"about": {
"@type": "MedicalCondition",
"name": "Brentuximab védotine",
"code": {
"@type": "MedicalCode",
"code": "D000079963",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.469"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cétuximab",
"alternateName": "Cetuximab",
"url": "https://questionsmedicales.fr/mesh/D000068818",
"about": {
"@type": "MedicalCondition",
"name": "Cétuximab",
"code": {
"@type": "MedicalCode",
"code": "D000068818",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Daclizumab",
"alternateName": "Daclizumab",
"url": "https://questionsmedicales.fr/mesh/D000077561",
"about": {
"@type": "MedicalCondition",
"name": "Daclizumab",
"code": {
"@type": "MedicalCode",
"code": "D000077561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.766"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dénosumab",
"alternateName": "Denosumab",
"url": "https://questionsmedicales.fr/mesh/D000069448",
"about": {
"@type": "MedicalCondition",
"name": "Dénosumab",
"code": {
"@type": "MedicalCode",
"code": "D000069448",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.782"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Gemtuzumab",
"alternateName": "Gemtuzumab",
"url": "https://questionsmedicales.fr/mesh/D000079982",
"about": {
"@type": "MedicalCondition",
"name": "Gemtuzumab",
"code": {
"@type": "MedicalCode",
"code": "D000079982",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.790"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inotuzumab ozogamicine",
"alternateName": "Inotuzumab Ozogamicin",
"url": "https://questionsmedicales.fr/mesh/D000080045",
"about": {
"@type": "MedicalCondition",
"name": "Inotuzumab ozogamicine",
"code": {
"@type": "MedicalCode",
"code": "D000080045",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.794"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ipilimumab",
"alternateName": "Ipilimumab",
"url": "https://questionsmedicales.fr/mesh/D000074324",
"about": {
"@type": "MedicalCondition",
"name": "Ipilimumab",
"code": {
"@type": "MedicalCode",
"code": "D000074324",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.798"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Natalizumab",
"alternateName": "Natalizumab",
"url": "https://questionsmedicales.fr/mesh/D000069442",
"about": {
"@type": "MedicalCondition",
"name": "Natalizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069442",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.813"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nivolumab",
"alternateName": "Nivolumab",
"url": "https://questionsmedicales.fr/mesh/D000077594",
"about": {
"@type": "MedicalCondition",
"name": "Nivolumab",
"code": {
"@type": "MedicalCode",
"code": "D000077594",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.829"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Omalizumab",
"alternateName": "Omalizumab",
"url": "https://questionsmedicales.fr/mesh/D000069444",
"about": {
"@type": "MedicalCondition",
"name": "Omalizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069444",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.844"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Palivizumab",
"alternateName": "Palivizumab",
"url": "https://questionsmedicales.fr/mesh/D000069455",
"about": {
"@type": "MedicalCondition",
"name": "Palivizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069455",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.860"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Panitumumab",
"alternateName": "Panitumumab",
"url": "https://questionsmedicales.fr/mesh/D000077544",
"about": {
"@type": "MedicalCondition",
"name": "Panitumumab",
"code": {
"@type": "MedicalCode",
"code": "D000077544",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.864"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ranibizumab",
"alternateName": "Ranibizumab",
"url": "https://questionsmedicales.fr/mesh/D000069579",
"about": {
"@type": "MedicalCondition",
"name": "Ranibizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.868"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Trastuzumab",
"alternateName": "Trastuzumab",
"url": "https://questionsmedicales.fr/mesh/D000068878",
"about": {
"@type": "MedicalCondition",
"name": "Trastuzumab",
"code": {
"@type": "MedicalCode",
"code": "D000068878",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.875"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ado-trastuzumab emtansine",
"alternateName": "Ado-Trastuzumab Emtansine",
"url": "https://questionsmedicales.fr/mesh/D000080044",
"about": {
"@type": "MedicalCondition",
"name": "Ado-trastuzumab emtansine",
"code": {
"@type": "MedicalCode",
"code": "D000080044",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.875.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Ado-trastuzumab emtansine",
"alternateName": "Ado-Trastuzumab Emtansine",
"url": "https://questionsmedicales.fr/mesh/D000080044",
"about": {
"@type": "MedicalCondition",
"name": "Ado-trastuzumab emtansine",
"code": {
"@type": "MedicalCode",
"code": "D000080044",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.875.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ustékinumab",
"alternateName": "Ustekinumab",
"url": "https://questionsmedicales.fr/mesh/D000069549",
"about": {
"@type": "MedicalCondition",
"name": "Ustékinumab",
"code": {
"@type": "MedicalCode",
"code": "D000069549",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.937"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Adalimumab",
"alternateName": "Adalimumab",
"url": "https://questionsmedicales.fr/mesh/D000068879",
"about": {
"@type": "MedicalCondition",
"name": "Adalimumab",
"code": {
"@type": "MedicalCode",
"code": "D000068879",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alemtuzumab",
"alternateName": "Alemtuzumab",
"url": "https://questionsmedicales.fr/mesh/D000074323",
"about": {
"@type": "MedicalCondition",
"name": "Alemtuzumab",
"code": {
"@type": "MedicalCode",
"code": "D000074323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Basiliximab",
"alternateName": "Basiliximab",
"url": "https://questionsmedicales.fr/mesh/D000077552",
"about": {
"@type": "MedicalCondition",
"name": "Basiliximab",
"code": {
"@type": "MedicalCode",
"code": "D000077552",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.407"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Bévacizumab",
"alternateName": "Bevacizumab",
"url": "https://questionsmedicales.fr/mesh/D000068258",
"about": {
"@type": "MedicalCondition",
"name": "Bévacizumab",
"code": {
"@type": "MedicalCode",
"code": "D000068258",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.438"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Brentuximab védotine",
"alternateName": "Brentuximab Vedotin",
"url": "https://questionsmedicales.fr/mesh/D000079963",
"about": {
"@type": "MedicalCondition",
"name": "Brentuximab védotine",
"code": {
"@type": "MedicalCode",
"code": "D000079963",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.469"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cétuximab",
"alternateName": "Cetuximab",
"url": "https://questionsmedicales.fr/mesh/D000068818",
"about": {
"@type": "MedicalCondition",
"name": "Cétuximab",
"code": {
"@type": "MedicalCode",
"code": "D000068818",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Daclizumab",
"alternateName": "Daclizumab",
"url": "https://questionsmedicales.fr/mesh/D000077561",
"about": {
"@type": "MedicalCondition",
"name": "Daclizumab",
"code": {
"@type": "MedicalCode",
"code": "D000077561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.766"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dénosumab",
"alternateName": "Denosumab",
"url": "https://questionsmedicales.fr/mesh/D000069448",
"about": {
"@type": "MedicalCondition",
"name": "Dénosumab",
"code": {
"@type": "MedicalCode",
"code": "D000069448",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.782"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Gemtuzumab",
"alternateName": "Gemtuzumab",
"url": "https://questionsmedicales.fr/mesh/D000079982",
"about": {
"@type": "MedicalCondition",
"name": "Gemtuzumab",
"code": {
"@type": "MedicalCode",
"code": "D000079982",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.790"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Inotuzumab ozogamicine",
"alternateName": "Inotuzumab Ozogamicin",
"url": "https://questionsmedicales.fr/mesh/D000080045",
"about": {
"@type": "MedicalCondition",
"name": "Inotuzumab ozogamicine",
"code": {
"@type": "MedicalCode",
"code": "D000080045",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.794"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ipilimumab",
"alternateName": "Ipilimumab",
"url": "https://questionsmedicales.fr/mesh/D000074324",
"about": {
"@type": "MedicalCondition",
"name": "Ipilimumab",
"code": {
"@type": "MedicalCode",
"code": "D000074324",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.798"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Natalizumab",
"alternateName": "Natalizumab",
"url": "https://questionsmedicales.fr/mesh/D000069442",
"about": {
"@type": "MedicalCondition",
"name": "Natalizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069442",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.813"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nivolumab",
"alternateName": "Nivolumab",
"url": "https://questionsmedicales.fr/mesh/D000077594",
"about": {
"@type": "MedicalCondition",
"name": "Nivolumab",
"code": {
"@type": "MedicalCode",
"code": "D000077594",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.829"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Omalizumab",
"alternateName": "Omalizumab",
"url": "https://questionsmedicales.fr/mesh/D000069444",
"about": {
"@type": "MedicalCondition",
"name": "Omalizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069444",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.844"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Palivizumab",
"alternateName": "Palivizumab",
"url": "https://questionsmedicales.fr/mesh/D000069455",
"about": {
"@type": "MedicalCondition",
"name": "Palivizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069455",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.860"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Panitumumab",
"alternateName": "Panitumumab",
"url": "https://questionsmedicales.fr/mesh/D000077544",
"about": {
"@type": "MedicalCondition",
"name": "Panitumumab",
"code": {
"@type": "MedicalCode",
"code": "D000077544",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.864"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ranibizumab",
"alternateName": "Ranibizumab",
"url": "https://questionsmedicales.fr/mesh/D000069579",
"about": {
"@type": "MedicalCondition",
"name": "Ranibizumab",
"code": {
"@type": "MedicalCode",
"code": "D000069579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.868"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Trastuzumab",
"alternateName": "Trastuzumab",
"url": "https://questionsmedicales.fr/mesh/D000068878",
"about": {
"@type": "MedicalCondition",
"name": "Trastuzumab",
"code": {
"@type": "MedicalCode",
"code": "D000068878",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.875"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ado-trastuzumab emtansine",
"alternateName": "Ado-Trastuzumab Emtansine",
"url": "https://questionsmedicales.fr/mesh/D000080044",
"about": {
"@type": "MedicalCondition",
"name": "Ado-trastuzumab emtansine",
"code": {
"@type": "MedicalCode",
"code": "D000080044",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.875.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Ado-trastuzumab emtansine",
"alternateName": "Ado-Trastuzumab Emtansine",
"url": "https://questionsmedicales.fr/mesh/D000080044",
"about": {
"@type": "MedicalCondition",
"name": "Ado-trastuzumab emtansine",
"code": {
"@type": "MedicalCode",
"code": "D000080044",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.875.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ustékinumab",
"alternateName": "Ustekinumab",
"url": "https://questionsmedicales.fr/mesh/D000069549",
"about": {
"@type": "MedicalCondition",
"name": "Ustékinumab",
"code": {
"@type": "MedicalCode",
"code": "D000069549",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.200.937"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps monoclonaux d'origine murine",
"alternateName": "Antibodies, Monoclonal, Murine-Derived",
"url": "https://questionsmedicales.fr/mesh/D058846",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps monoclonaux d'origine murine",
"code": {
"@type": "MedicalCode",
"code": "D058846",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.284"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Rituximab",
"alternateName": "Rituximab",
"url": "https://questionsmedicales.fr/mesh/D000069283",
"about": {
"@type": "MedicalCondition",
"name": "Rituximab",
"code": {
"@type": "MedicalCode",
"code": "D000069283",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.284.785"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Rituximab",
"alternateName": "Rituximab",
"url": "https://questionsmedicales.fr/mesh/D000069283",
"about": {
"@type": "MedicalCondition",
"name": "Rituximab",
"code": {
"@type": "MedicalCode",
"code": "D000069283",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.284.785"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Infliximab",
"alternateName": "Infliximab",
"url": "https://questionsmedicales.fr/mesh/D000069285",
"about": {
"@type": "MedicalCondition",
"name": "Infliximab",
"code": {
"@type": "MedicalCode",
"code": "D000069285",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.224.642"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antitumoraux",
"alternateName": "Antibodies, Neoplasm",
"url": "https://questionsmedicales.fr/mesh/D000912",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antitumoraux",
"code": {
"@type": "MedicalCode",
"code": "D000912",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.240"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps neutralisants",
"alternateName": "Antibodies, Neutralizing",
"url": "https://questionsmedicales.fr/mesh/D057134",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps neutralisants",
"code": {
"@type": "MedicalCode",
"code": "D057134",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.244"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps neutralisants à large spectre",
"alternateName": "Broadly Neutralizing Antibodies",
"url": "https://questionsmedicales.fr/mesh/D000080908",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps neutralisants à large spectre",
"code": {
"@type": "MedicalCode",
"code": "D000080908",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.244.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Anticorps phospho-spécifiques",
"alternateName": "Antibodies, Phospho-Specific",
"url": "https://questionsmedicales.fr/mesh/D045163",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps phospho-spécifiques",
"code": {
"@type": "MedicalCode",
"code": "D045163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.248"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antiprotozoaires",
"alternateName": "Antibodies, Protozoan",
"url": "https://questionsmedicales.fr/mesh/D000913",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antiprotozoaires",
"code": {
"@type": "MedicalCode",
"code": "D000913",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.252"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antiviraux",
"alternateName": "Antibodies, Viral",
"url": "https://questionsmedicales.fr/mesh/D000914",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antiviraux",
"code": {
"@type": "MedicalCode",
"code": "D000914",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps antideltarétrovirus",
"alternateName": "Deltaretrovirus Antibodies",
"url": "https://questionsmedicales.fr/mesh/D015480",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antideltarétrovirus",
"code": {
"@type": "MedicalCode",
"code": "D015480",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.150"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-VIH",
"alternateName": "HIV Antibodies",
"url": "https://questionsmedicales.fr/mesh/D015483",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-VIH",
"code": {
"@type": "MedicalCode",
"code": "D015483",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.150.440"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-HTLVI",
"alternateName": "HTLV-I Antibodies",
"url": "https://questionsmedicales.fr/mesh/D015481",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-HTLVI",
"code": {
"@type": "MedicalCode",
"code": "D015481",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.150.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-HTLVII",
"alternateName": "HTLV-II Antibodies",
"url": "https://questionsmedicales.fr/mesh/D015482",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-HTLVII",
"code": {
"@type": "MedicalCode",
"code": "D015482",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.150.510"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-VIH",
"alternateName": "HIV Antibodies",
"url": "https://questionsmedicales.fr/mesh/D015483",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-VIH",
"code": {
"@type": "MedicalCode",
"code": "D015483",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.150.440"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-HTLVI",
"alternateName": "HTLV-I Antibodies",
"url": "https://questionsmedicales.fr/mesh/D015481",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-HTLVI",
"code": {
"@type": "MedicalCode",
"code": "D015481",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.150.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-HTLVII",
"alternateName": "HTLV-II Antibodies",
"url": "https://questionsmedicales.fr/mesh/D015482",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-HTLVII",
"code": {
"@type": "MedicalCode",
"code": "D015482",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.150.510"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite",
"alternateName": "Hepatitis Antibodies",
"url": "https://questionsmedicales.fr/mesh/D006508",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite",
"code": {
"@type": "MedicalCode",
"code": "D006508",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite A",
"alternateName": "Hepatitis A Antibodies",
"url": "https://questionsmedicales.fr/mesh/D035922",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite A",
"code": {
"@type": "MedicalCode",
"code": "D035922",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.251"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite B",
"alternateName": "Hepatitis B Antibodies",
"url": "https://questionsmedicales.fr/mesh/D006510",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite B",
"code": {
"@type": "MedicalCode",
"code": "D006510",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.504"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite C",
"alternateName": "Hepatitis C Antibodies",
"url": "https://questionsmedicales.fr/mesh/D018937",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite C",
"code": {
"@type": "MedicalCode",
"code": "D018937",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.510"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite A",
"alternateName": "Hepatitis A Antibodies",
"url": "https://questionsmedicales.fr/mesh/D035922",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite A",
"code": {
"@type": "MedicalCode",
"code": "D035922",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.251"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite B",
"alternateName": "Hepatitis B Antibodies",
"url": "https://questionsmedicales.fr/mesh/D006510",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite B",
"code": {
"@type": "MedicalCode",
"code": "D006510",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.504"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps de l'hépatite C",
"alternateName": "Hepatitis C Antibodies",
"url": "https://questionsmedicales.fr/mesh/D018937",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps de l'hépatite C",
"code": {
"@type": "MedicalCode",
"code": "D018937",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.254.450.510"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Autoanticorps",
"alternateName": "Autoantibodies",
"url": "https://questionsmedicales.fr/mesh/D001323",
"about": {
"@type": "MedicalCondition",
"name": "Autoanticorps",
"code": {
"@type": "MedicalCode",
"code": "D001323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-protéines citrullinées",
"alternateName": "Anti-Citrullinated Protein Antibodies",
"url": "https://questionsmedicales.fr/mesh/D000075422",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-protéines citrullinées",
"code": {
"@type": "MedicalCode",
"code": "D000075422",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.095"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antinucléaires",
"alternateName": "Antibodies, Antinuclear",
"url": "https://questionsmedicales.fr/mesh/D000974",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antinucléaires",
"code": {
"@type": "MedicalCode",
"code": "D000974",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.204"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps antiphospholipides",
"alternateName": "Antibodies, Antiphospholipid",
"url": "https://questionsmedicales.fr/mesh/D017152",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps antiphospholipides",
"code": {
"@type": "MedicalCode",
"code": "D017152",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.210"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anticorps anticardiolipines",
"alternateName": "Antibodies, Anticardiolipin",
"url": "https://questionsmedicales.fr/mesh/D017153",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anticardiolipines",
"code": {
"@type": "MedicalCode",
"code": "D017153",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.210.100"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anticardiolipines",
"alternateName": "Antibodies, Anticardiolipin",
"url": "https://questionsmedicales.fr/mesh/D017153",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anticardiolipines",
"code": {
"@type": "MedicalCode",
"code": "D017153",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.210.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur néphritique C3",
"alternateName": "Complement C3 Nephritic Factor",
"url": "https://questionsmedicales.fr/mesh/D003178",
"about": {
"@type": "MedicalCondition",
"name": "Facteur néphritique C3",
"code": {
"@type": "MedicalCode",
"code": "D003178",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoconglutinines",
"alternateName": "Immunoconglutinins",
"url": "https://questionsmedicales.fr/mesh/D037561",
"about": {
"@type": "MedicalCondition",
"name": "Immunoconglutinines",
"code": {
"@type": "MedicalCode",
"code": "D037561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.390"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobulines thyréostimulantes",
"alternateName": "Immunoglobulins, Thyroid-Stimulating",
"url": "https://questionsmedicales.fr/mesh/D018828",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobulines thyréostimulantes",
"code": {
"@type": "MedicalCode",
"code": "D018828",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.480"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur rhumatoïde",
"alternateName": "Rheumatoid Factor",
"url": "https://questionsmedicales.fr/mesh/D012217",
"about": {
"@type": "MedicalCondition",
"name": "Facteur rhumatoïde",
"code": {
"@type": "MedicalCode",
"code": "D012217",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.323.732"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Abatacept",
"alternateName": "Abatacept",
"url": "https://questionsmedicales.fr/mesh/D000069594",
"about": {
"@type": "MedicalCondition",
"name": "Abatacept",
"code": {
"@type": "MedicalCode",
"code": "D000069594",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.580.225"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Isotypes des immunoglobulines",
"alternateName": "Immunoglobulin Isotypes",
"url": "https://questionsmedicales.fr/mesh/D007132",
"about": {
"@type": "MedicalCondition",
"name": "Isotypes des immunoglobulines",
"code": {
"@type": "MedicalCode",
"code": "D007132",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline A",
"alternateName": "Immunoglobulin A",
"url": "https://questionsmedicales.fr/mesh/D007070",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline A",
"code": {
"@type": "MedicalCode",
"code": "D007070",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.026"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline A sécrétoire",
"alternateName": "Immunoglobulin A, Secretory",
"url": "https://questionsmedicales.fr/mesh/D007071",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline A sécrétoire",
"code": {
"@type": "MedicalCode",
"code": "D007071",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.026.030"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline A sécrétoire",
"alternateName": "Immunoglobulin A, Secretory",
"url": "https://questionsmedicales.fr/mesh/D007071",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline A sécrétoire",
"code": {
"@type": "MedicalCode",
"code": "D007071",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.026.030"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline D",
"alternateName": "Immunoglobulin D",
"url": "https://questionsmedicales.fr/mesh/D007072",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline D",
"code": {
"@type": "MedicalCode",
"code": "D007072",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.251"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline E",
"alternateName": "Immunoglobulin E",
"url": "https://questionsmedicales.fr/mesh/D007073",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline E",
"code": {
"@type": "MedicalCode",
"code": "D007073",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.312"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline G",
"alternateName": "Immunoglobulin G",
"url": "https://questionsmedicales.fr/mesh/D007074",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline G",
"code": {
"@type": "MedicalCode",
"code": "D007074",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.393"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "LATS",
"alternateName": "Long-Acting Thyroid Stimulator",
"url": "https://questionsmedicales.fr/mesh/D008135",
"about": {
"@type": "MedicalCondition",
"name": "LATS",
"code": {
"@type": "MedicalCode",
"code": "D008135",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.393.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Muromonab-CD3",
"alternateName": "Muromonab-CD3",
"url": "https://questionsmedicales.fr/mesh/D016853",
"about": {
"@type": "MedicalCondition",
"name": "Muromonab-CD3",
"code": {
"@type": "MedicalCode",
"code": "D016853",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.393.570"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline Rh",
"alternateName": "Rho(D) Immune Globulin",
"url": "https://questionsmedicales.fr/mesh/D018029",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline Rh",
"code": {
"@type": "MedicalCode",
"code": "D018029",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.393.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "LATS",
"alternateName": "Long-Acting Thyroid Stimulator",
"url": "https://questionsmedicales.fr/mesh/D008135",
"about": {
"@type": "MedicalCondition",
"name": "LATS",
"code": {
"@type": "MedicalCode",
"code": "D008135",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.393.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Muromonab-CD3",
"alternateName": "Muromonab-CD3",
"url": "https://questionsmedicales.fr/mesh/D016853",
"about": {
"@type": "MedicalCondition",
"name": "Muromonab-CD3",
"code": {
"@type": "MedicalCode",
"code": "D016853",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.393.570"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline Rh",
"alternateName": "Rho(D) Immune Globulin",
"url": "https://questionsmedicales.fr/mesh/D018029",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline Rh",
"code": {
"@type": "MedicalCode",
"code": "D018029",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.393.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobuline M",
"alternateName": "Immunoglobulin M",
"url": "https://questionsmedicales.fr/mesh/D007075",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobuline M",
"code": {
"@type": "MedicalCode",
"code": "D007075",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.619.574"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Immunoglobulines par voie veineuse",
"alternateName": "Immunoglobulins, Intravenous",
"url": "https://questionsmedicales.fr/mesh/D016756",
"about": {
"@type": "MedicalCondition",
"name": "Immunoglobulines par voie veineuse",
"code": {
"@type": "MedicalCode",
"code": "D016756",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.632"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Anticorps anti-insuline",
"alternateName": "Insulin Antibodies",
"url": "https://questionsmedicales.fr/mesh/D007330",
"about": {
"@type": "MedicalCondition",
"name": "Anticorps anti-insuline",
"code": {
"@type": "MedicalCode",
"code": "D007330",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.656"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alloanticorps",
"alternateName": "Isoantibodies",
"url": "https://questionsmedicales.fr/mesh/D007518",
"about": {
"@type": "MedicalCondition",
"name": "Alloanticorps",
"code": {
"@type": "MedicalCode",
"code": "D007518",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.664"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Planticorps",
"alternateName": "Plantibodies",
"url": "https://questionsmedicales.fr/mesh/D046549",
"about": {
"@type": "MedicalCondition",
"name": "Planticorps",
"code": {
"@type": "MedicalCode",
"code": "D046549",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.820"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Précipitines",
"alternateName": "Precipitins",
"url": "https://questionsmedicales.fr/mesh/D011234",
"about": {
"@type": "MedicalCondition",
"name": "Précipitines",
"code": {
"@type": "MedicalCode",
"code": "D011234",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.837"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Réagines",
"alternateName": "Reagins",
"url": "https://questionsmedicales.fr/mesh/D011935",
"about": {
"@type": "MedicalCondition",
"name": "Réagines",
"code": {
"@type": "MedicalCode",
"code": "D011935",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.377.715.548.114.890"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Anticorps",
"alternateName": "Antibodies",
"code": {
"@type": "MedicalCode",
"code": "D000906",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anita Bandrowski",
"url": "https://questionsmedicales.fr/author/Anita%20Bandrowski",
"affiliation": {
"@type": "Organization",
"name": "Center for Research in Biological Systems, University of California , La Jolla, CA, USA."
}
},
{
"@type": "Person",
"name": "Sophana Chea",
"url": "https://questionsmedicales.fr/author/Sophana%20Chea",
"affiliation": {
"@type": "Organization",
"name": "International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia."
}
},
{
"@type": "Person",
"name": "Laura Willen",
"url": "https://questionsmedicales.fr/author/Laura%20Willen",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States."
}
},
{
"@type": "Person",
"name": "Sreynik Nhek",
"url": "https://questionsmedicales.fr/author/Sreynik%20Nhek",
"affiliation": {
"@type": "Organization",
"name": "International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia."
}
},
{
"@type": "Person",
"name": "Piseth Ly",
"url": "https://questionsmedicales.fr/author/Piseth%20Ly",
"affiliation": {
"@type": "Organization",
"name": "International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Biological effectiveness and relative biological effectiveness of ion beams for in-vitro cell irradiation.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35642350",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/cas.15446"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Monte Carlo study of the relative biological effectiveness in surface brachytherapy.",
"datePublished": "2022-06-16",
"url": "https://questionsmedicales.fr/article/35644023",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mp.15774"
}
},
{
"@type": "ScholarlyArticle",
"name": "Increased relative biological effectiveness and periventricular radiosensitivity in proton therapy of glioma patients.",
"datePublished": "2022-11-23",
"url": "https://questionsmedicales.fr/article/36435337",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.radonc.2022.11.011"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hypoxia adapted relative biological effectiveness models for proton therapy: a simulation study.",
"datePublished": "2022-11-04",
"url": "https://questionsmedicales.fr/article/36260973",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1088/2057-1976/ac9b5d"
}
},
{
"@type": "ScholarlyArticle",
"name": "A systematic review of clinical studies on variable proton Relative Biological Effectiveness (RBE).",
"datePublished": "2022-08-18",
"url": "https://questionsmedicales.fr/article/35988776",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.radonc.2022.08.014"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Globulines",
"item": "https://questionsmedicales.fr/mesh/D005916"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sérum-globulines",
"item": "https://questionsmedicales.fr/mesh/D012712"
},
{
"@type": "ListItem",
"position": 6,
"name": "Immunoglobulines",
"item": "https://questionsmedicales.fr/mesh/D007136"
},
{
"@type": "ListItem",
"position": 7,
"name": "Anticorps",
"item": "https://questionsmedicales.fr/mesh/D000906"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Anticorps - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Anticorps",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Anticorps",
"description": "Comment détecte-t-on les anticorps dans le sang ?\nQuels tests sont utilisés pour les anticorps spécifiques ?\nLes anticorps peuvent-ils indiquer une infection ?\nQu'est-ce qu'un titre d'anticorps ?\nLes anticorps peuvent-ils être détectés chez les nouveau-nés ?",
"url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Relative+Biological+Effectiveness#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Anticorps",
"description": "Quels symptômes indiquent une réponse immunitaire ?\nLes anticorps causent-ils des symptômes ?\nComment les anticorps affectent-ils les allergies ?\nLes anticorps peuvent-ils causer des maladies auto-immunes ?\nQuels anticorps sont liés aux infections virales ?",
"url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Relative+Biological+Effectiveness#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Anticorps",
"description": "Comment les vaccins stimulent-ils la production d'anticorps ?\nLes anticorps peuvent-ils être transférés par le lait maternel ?\nComment maintenir un système immunitaire fort ?\nLes anticorps peuvent-ils être utilisés pour prévenir le COVID-19 ?\nLes anticorps sont-ils efficaces contre toutes les infections ?",
"url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Relative+Biological+Effectiveness#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Anticorps",
"description": "Comment les anticorps sont-ils utilisés en thérapie ?\nLes anticorps peuvent-ils être administrés par injection ?\nQu'est-ce que l'immunothérapie par anticorps ?\nLes anticorps peuvent-ils être utilisés pour prévenir des maladies ?\nQuels sont les effets secondaires des traitements par anticorps ?",
"url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Relative+Biological+Effectiveness#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Anticorps",
"description": "Quels sont les risques d'une surproduction d'anticorps ?\nLes anticorps peuvent-ils causer des réactions allergiques ?\nQuelles complications peuvent survenir avec des anticorps monoclonaux ?\nLes anticorps peuvent-ils interférer avec d'autres traitements ?\nQuelles sont les complications des maladies auto-immunes ?",
"url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Relative+Biological+Effectiveness#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Anticorps",
"description": "Quels facteurs augmentent le risque de maladies auto-immunes ?\nLe stress influence-t-il la production d'anticorps ?\nL'âge influence-t-il la réponse des anticorps ?\nLes infections antérieures affectent-elles la production d'anticorps ?\nLes habitudes alimentaires influencent-elles les anticorps ?",
"url": "https://questionsmedicales.fr/mesh/D000906?mesh_terms=Relative+Biological+Effectiveness#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecte-t-on les anticorps dans le sang ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "On utilise des tests sérologiques comme l'ELISA pour mesurer les anticorps."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les anticorps spécifiques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme l'immunofluorescence ou les tests d'agglutination sont utilisés."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils indiquer une infection ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la présence d'anticorps spécifiques peut indiquer une infection antérieure."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'un titre d'anticorps ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une mesure de la concentration d'anticorps dans le sang, indiquant l'immunité."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils être détectés chez les nouveau-nés ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anticorps maternels peuvent être détectés chez les nouveau-nés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réponse immunitaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, fatigue, et inflammation peuvent indiquer une réponse immunitaire active."
}
},
{
"@type": "Question",
"name": "Les anticorps causent-ils des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ce sont les maladies ou infections que les anticorps combattent qui causent des symptômes."
}
},
{
"@type": "Question",
"name": "Comment les anticorps affectent-ils les allergies ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticorps IgE sont impliqués dans les réactions allergiques, provoquant des symptômes."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils causer des maladies auto-immunes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anticorps peuvent attaquer les tissus sains, entraînant des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels anticorps sont liés aux infections virales ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticorps IgM et IgG sont souvent associés aux infections virales."
}
},
{
"@type": "Question",
"name": "Comment les vaccins stimulent-ils la production d'anticorps ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccins introduisent des antigènes, entraînant la production d'anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils être transférés par le lait maternel ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anticorps maternels sont transférés au bébé par le lait maternel, offrant une protection."
}
},
{
"@type": "Question",
"name": "Comment maintenir un système immunitaire fort ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice et le sommeil aident à maintenir un système immunitaire fort."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils être utilisés pour prévenir le COVID-19 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements par anticorps monoclonaux sont utilisés pour prévenir les formes graves du COVID-19."
}
},
{
"@type": "Question",
"name": "Les anticorps sont-ils efficaces contre toutes les infections ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur efficacité dépend du type d'infection et de la réponse immunitaire individuelle."
}
},
{
"@type": "Question",
"name": "Comment les anticorps sont-ils utilisés en thérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anticorps monoclonaux sont utilisés pour traiter diverses maladies, y compris le cancer."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils être administrés par injection ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anticorps peuvent être administrés par injection pour traiter certaines maladies."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'immunothérapie par anticorps ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui utilise des anticorps pour renforcer la réponse immunitaire contre le cancer."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils être utilisés pour prévenir des maladies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anticorps spécifiques peuvent être administrés pour prévenir certaines infections."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements par anticorps ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions allergiques et des infections."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surproduction d'anticorps ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surproduction peut entraîner des maladies auto-immunes ou des allergies graves."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils causer des réactions allergiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains anticorps peuvent provoquer des réactions allergiques en réponse à des allergènes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anticorps monoclonaux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections, des réactions allergiques et des effets secondaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les anticorps peuvent-ils interférer avec d'autres traitements ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains anticorps peuvent interagir avec d'autres médicaments, affectant leur efficacité."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications des maladies auto-immunes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des dommages aux organes, des infections et une qualité de vie réduite."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de maladies auto-immunes ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques, environnementaux et hormonaux peuvent augmenter ce risque."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il la production d'anticorps ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la réponse immunitaire et la production d'anticorps."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la réponse des anticorps ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réponse des anticorps peut diminuer avec l'âge, rendant les personnes âgées plus vulnérables."
}
},
{
"@type": "Question",
"name": "Les infections antérieures affectent-elles la production d'anticorps ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections antérieures peuvent influencer la mémoire immunitaire et la production d'anticorps."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles les anticorps ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments peut soutenir la production d'anticorps et la santé immunitaire."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/04/2025
Contenu vérifié selon les dernières recommandations médicales
└─
Anticorps anti-idiotypiques
Antibodies, Anti-Idiotypic
D000888
-
D12.776.377.715.548.114.071
└─
Anticorps anti-archéens
Antibodies, Archaeal
D019844
-
D12.776.377.715.548.114.107
└─
Anticorps antibactériens
Antibodies, Bacterial
D000907
-
D12.776.377.715.548.114.125
└─
Anticorps bispécifiques
Antibodies, Bispecific
D018033
-
D12.776.377.715.548.114.134
└─
Anticorps bloquants
Antibodies, Blocking
D019138
-
D12.776.377.715.548.114.143
└─
Anticorps catalytiques
Antibodies, Catalytic
D017151
-
D12.776.377.715.548.114.167
└─
Anticorps antifongiques
Antibodies, Fungal
D000908
-
D12.776.377.715.548.114.179
└─
Anticorps antihelminthe
Antibodies, Helminth
D000909
-
D12.776.377.715.548.114.185
└─
Anticorps hétérophiles
Antibodies, Heterophile
D000910
-
D12.776.377.715.548.114.191
└─
Anticorps monoclonaux
Antibodies, Monoclonal
D000911
-
D12.776.377.715.548.114.224
└─
Anticorps antitumoraux
Antibodies, Neoplasm
D000912
-
D12.776.377.715.548.114.240
└─
Anticorps neutralisants
Antibodies, Neutralizing
D057134
-
D12.776.377.715.548.114.244
└─
Anticorps phospho-spécifiques
Antibodies, Phospho-Specific
D045163
-
D12.776.377.715.548.114.248
└─
Anticorps antiprotozoaires
Antibodies, Protozoan
D000913
-
D12.776.377.715.548.114.252
└─
Anticorps antiviraux
Antibodies, Viral
D000914
-
D12.776.377.715.548.114.254
└─
Autoanticorps
Autoantibodies
D001323
-
D12.776.377.715.548.114.323
└─
Isotypes des immunoglobulines
Immunoglobulin Isotypes
D007132
-
D12.776.377.715.548.114.619
└─
Immunoglobulines par voie veineuse
Immunoglobulins, Intravenous
D016756
-
D12.776.377.715.548.114.632
└─
Anticorps anti-insuline
Insulin Antibodies
D007330
-
D12.776.377.715.548.114.656
└─
Alloanticorps
Isoantibodies
D007518
-
D12.776.377.715.548.114.664
└─
Planticorps
Plantibodies
D046549
-
D12.776.377.715.548.114.820
└─
Précipitines
Precipitins
D011234
-
D12.776.377.715.548.114.837
└─
Réagines
Reagins
D011935
-
D12.776.377.715.548.114.890
└─└─
Antistreptolysine
Antistreptolysin
D000989
-
D12.776.377.715.548.114.125.288
└─└─
Anticorps monoclonaux humanisés
Antibodies, Monoclonal, Humanized
D061067
-
D12.776.377.715.548.114.224.200
└─└─
Anticorps monoclonaux d'origine murine
Antibodies, Monoclonal, Murine-Derived
D058846
-
D12.776.377.715.548.114.224.284
└─└─
Infliximab
Infliximab
D000069285
-
D12.776.377.715.548.114.224.642
└─└─
Anticorps neutralisants à large spectre
Broadly Neutralizing Antibodies
D000080908
-
D12.776.377.715.548.114.244.500
└─└─
Anticorps antideltarétrovirus
Deltaretrovirus Antibodies
D015480
-
D12.776.377.715.548.114.254.150
└─└─
Anticorps de l'hépatite
Hepatitis Antibodies
D006508
-
D12.776.377.715.548.114.254.450
└─└─
Anticorps anti-protéines citrullinées
Anti-Citrullinated Protein Antibodies
D000075422
-
D12.776.377.715.548.114.323.095
└─└─
Anticorps antinucléaires
Antibodies, Antinuclear
D000974
-
D12.776.377.715.548.114.323.204
└─└─
Anticorps antiphospholipides
Antibodies, Antiphospholipid
D017152
-
D12.776.377.715.548.114.323.210
└─└─
Facteur néphritique C3
Complement C3 Nephritic Factor
D003178
-
D12.776.377.715.548.114.323.300
└─└─
Immunoconglutinines
Immunoconglutinins
D037561
-
D12.776.377.715.548.114.323.390
└─└─
Immunoglobulines thyréostimulantes
Immunoglobulins, Thyroid-Stimulating
D018828
-
D12.776.377.715.548.114.323.480
└─└─
Facteur rhumatoïde
Rheumatoid Factor
D012217
-
D12.776.377.715.548.114.323.732
└─└─
Abatacept
Abatacept
D000069594
-
D12.776.377.715.548.114.580.225
└─└─
Immunoglobuline A
Immunoglobulin A
D007070
-
D12.776.377.715.548.114.619.026
└─└─
Immunoglobuline D
Immunoglobulin D
D007072
-
D12.776.377.715.548.114.619.251
└─└─
Immunoglobuline E
Immunoglobulin E
D007073
-
D12.776.377.715.548.114.619.312
└─└─
Immunoglobuline G
Immunoglobulin G
D007074
-
D12.776.377.715.548.114.619.393
└─└─
Immunoglobuline M
Immunoglobulin M
D007075
-
D12.776.377.715.548.114.619.574
└─└─└─
Adalimumab
Adalimumab
D000068879
-
D12.776.377.715.548.114.224.200.250
└─└─└─
Alemtuzumab
Alemtuzumab
D000074323
-
D12.776.377.715.548.114.224.200.375
└─└─└─
Basiliximab
Basiliximab
D000077552
-
D12.776.377.715.548.114.224.200.407
└─└─└─
Bévacizumab
Bevacizumab
D000068258
-
D12.776.377.715.548.114.224.200.438
└─└─└─
Brentuximab védotine
Brentuximab Vedotin
D000079963
-
D12.776.377.715.548.114.224.200.469
└─└─└─
Cétuximab
Cetuximab
D000068818
-
D12.776.377.715.548.114.224.200.750
└─└─└─
Daclizumab
Daclizumab
D000077561
-
D12.776.377.715.548.114.224.200.766
└─└─└─
Dénosumab
Denosumab
D000069448
-
D12.776.377.715.548.114.224.200.782
└─└─└─
Gemtuzumab
Gemtuzumab
D000079982
-
D12.776.377.715.548.114.224.200.790
└─└─└─
Inotuzumab ozogamicine
Inotuzumab Ozogamicin
D000080045
-
D12.776.377.715.548.114.224.200.794
└─└─└─
Ipilimumab
Ipilimumab
D000074324
-
D12.776.377.715.548.114.224.200.798
└─└─└─
Natalizumab
Natalizumab
D000069442
-
D12.776.377.715.548.114.224.200.813
└─└─└─
Nivolumab
Nivolumab
D000077594
-
D12.776.377.715.548.114.224.200.829
└─└─└─
Omalizumab
Omalizumab
D000069444
-
D12.776.377.715.548.114.224.200.844
└─└─└─
Palivizumab
Palivizumab
D000069455
-
D12.776.377.715.548.114.224.200.860
└─└─└─
Panitumumab
Panitumumab
D000077544
-
D12.776.377.715.548.114.224.200.864
└─└─└─
Ranibizumab
Ranibizumab
D000069579
-
D12.776.377.715.548.114.224.200.868
└─└─└─
Trastuzumab
Trastuzumab
D000068878
-
D12.776.377.715.548.114.224.200.875
└─└─└─
Ustékinumab
Ustekinumab
D000069549
-
D12.776.377.715.548.114.224.200.937
└─└─└─
Rituximab
Rituximab
D000069283
-
D12.776.377.715.548.114.224.284.785
└─└─└─
Anticorps anti-VIH
HIV Antibodies
D015483
-
D12.776.377.715.548.114.254.150.440
└─└─└─
Anticorps anti-HTLVI
HTLV-I Antibodies
D015481
-
D12.776.377.715.548.114.254.150.500
└─└─└─
Anticorps anti-HTLVII
HTLV-II Antibodies
D015482
-
D12.776.377.715.548.114.254.150.510
└─└─└─
Anticorps de l'hépatite A
Hepatitis A Antibodies
D035922
-
D12.776.377.715.548.114.254.450.251
└─└─└─
Anticorps de l'hépatite B
Hepatitis B Antibodies
D006510
-
D12.776.377.715.548.114.254.450.504
└─└─└─
Anticorps de l'hépatite C
Hepatitis C Antibodies
D018937
-
D12.776.377.715.548.114.254.450.510
└─└─└─
Anticorps anticardiolipines
Antibodies, Anticardiolipin
D017153
-
D12.776.377.715.548.114.323.210.100
└─└─└─
Immunoglobuline A sécrétoire
Immunoglobulin A, Secretory
D007071
-
D12.776.377.715.548.114.619.026.030
└─└─└─
LATS
Long-Acting Thyroid Stimulator
D008135
-
D12.776.377.715.548.114.619.393.550
└─└─└─
Muromonab-CD3
Muromonab-CD3
D016853
-
D12.776.377.715.548.114.619.393.570
└─└─└─
Immunoglobuline Rh
Rho(D) Immune Globulin
D018029
-
D12.776.377.715.548.114.619.393.700
└─└─└─└─
Ado-trastuzumab emtansine
Ado-Trastuzumab Emtansine
D000080044
-
D12.776.377.715.548.114.224.200.875.500
3 publications dans cette catégorie
Affiliations :
Center for Research in Biological Systems, University of California , La Jolla, CA, USA.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
National Center for Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom Penh, Cambodia.
National Dengue Control Program, Ministry of Health, Phnom Penh, Cambodia.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
National Center for Parasitology, Entomology, and Malaria Control, Ministry of Health, Phnom Penh, Cambodia.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
2 publications dans cette catégorie
Affiliations :
International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, Phnom Penh, Cambodia.
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Publications dans "Anticorps" :
Biological effectiveness and relative biological effectiveness are critical for proton and ion beam radiotherapy. However, the relationship between the two quantities and physical character of ion bea...
This work aims to simulate clustered DNA damage from ionizing radiation and estimate the relative biological effectiveness (RBE) for radionuclide (rBT)- and electronic (eBT)-based surface brachytherap...
Damage from ionizing radiation has been studied using the Monte Carlo Damage Simulation algorithm using as input the primary electron fluence simulated using a state-of-the-art MC code, PENELOPE-2018....
For rBT, an RBE value of about 1.01 has been found for the applicators and phantoms considered. In the case of eBT, RBE values for the Esteya system show an almost constant RBE value of about 1.06 for...
Current clinical practice does not incorporate biological effects in surface brachytherapy. Therefore, the same absorbed dose is administered to the patients independently on the particularities of th...
Currently, there is an intense debate on variations in intra-cerebral radiosensitivity and relative biological effectiveness (RBE) in proton therapy of primary brain tumours. Here, both effects were r...
In total, 42 WHO grade 2-3 glioma patients out of a consecutive patient cohort having received (adjuvant) proton radio(chemo)therapy between 2014 and 2017 were eligible for analysis. RIBI lesions (sym...
In total, 64 RIBI lesions were diagnosed in 21 patients. The median time between start of proton radio(chemo)therapy and RIBI appearance was 10.2 months. Median distances of the RIBI volume centres to...
In this glioma cohort, an increased radiosensitivity within the PVR was observed as well as a spatial correlation of RIBI with an increased RBE. Both need to be considered when delivering radio(chemo)...
In proton therapy, a constant relative biological effectiveness (RBE) factor of 1.1 is applied although the RBE has been shown to depend on factors including the Linear Energy Transfer (LET). The biol...
Recently, a number of clinical studies have explored links between possible Relative Biological Effectiveness (RBE) elevations and patient toxicities and/or image changes following proton therapy. Our...
A relative biological effectiveness (RBE) of 1.1 is used for proton therapy though clinical evidence of varying RBE was raised. Clinical studies on RBE variability have been conducted for decades for ...
The Wedenberg and Q models, both predicting RBE...
The model parameter of the Q model was observed to be similar for different ions (in contrast to LET). The Q model was trained without any prior knowledge of proton data. For proton RBE, the differenc...
A simple linear RBE model using Q instead of LET was proposed and tested to be able to predict proton RBE using model parameter trained based on only RBE data of other particles in a clinical proton e...
In treatment planning for proton therapy a constant Relative Biological Effectiveness (RBE) of 1.1 is used, disregarding variations with linear energy transfer, clinical endpoint, or fractionation....
To present a methodology to analyze the variation of RBE with fractionation from clinical data of tumor control probability (TCP) and to apply it to study the response of prostate cancer to proton the...
We analyzed the dependence of the RBE on the dose per fraction by using the LQ model and the Poisson TCP formalism. Clinical tumor control probabilities for prostate cancer (low and intermediate risk)...
The theoretical analysis of the dependence of the RBE on the dose per fraction showed three distinct regions with RBE monotonically decreasing, increasing or staying constant with the dose per fractio...
In this study, we have presented a methodology to analyze the RBE for different fractionations, and we used it to study clinical data for prostate cancer and evaluate the RBE versus dose per fraction....
Relative biological effectiveness is a radiobiological parameter relevant in radiotherapy planning and useful in evaluating the physiological impact of radiation in different tissues. Targeted radionu...
The effectiveness of ionizing radiation regarding DNA damage induction depends on its spatial energy deposition pattern. For electrons an increased effectiveness is observed at low kinetic energies du...
A model is presented, which enables the calculation of the double-strand-break (DSB) yield and the relative biological effectiveness (RBE) for DSB induction of electrons....
The model applies the mean free path between two ionizations and the assumption that two ionizations within a certain threshold distance are necessary to potentially lead to a DSB. Next to an expressi...
This local RBE allows a better understanding of microscopic processes resulting from radiation and can be used, for instance, to describe the mean effectiveness of the mixed electron radiation field a...
The presented model reflects the experimentally observed increased effectiveness of low-energetic electrons. It will be used in a future work to improve RBE predictions for ions performed with the loc...
The study objective was to validate the relative biological effectiveness (RBE) in RayStation for carbon-ion radiotherapy (CIRT) using the Syngo treatment planning system as reference....
Local effect model I was established in RayStation (Ray-LEM) with the same parameters as in LEM I in Syngo (Syngo-LEM). Three cube plans covering most of the tumors treated at our center were generate...
The calibration increased the RBEmax by 2.3% to raise the Ray-LEM RBE. The target mean RBE deviations in the phantom evaluation plans were median: 0.0 (minimum: - 1.1 to maximum: 0.7) %, and the targe...
The residual RBE difference between RayStation and Syngo was found to be ≤ 1.0%. Thus, we can propose to use RayStation for clinical CIRT treatment planning. However, the potential differences due to ...